Scalper1 News
Gilead Sciences (GILD) said Monday that its two-drug combo had succeeded against six different genotypes of the hepatitis C virus (HCV) in four late-stage clinical trials. Gilead’s studies combined sofosbuvir — which is sold separately as Sovaldi and is also an ingredient in Harvoni — with a new drug candidate called velpatasvir. Some cohorts took ribavirin, an older HCV pill, in place of velpatasvir. The patients on sofosbuvir/velpatasvir for 12 Scalper1 News
Scalper1 News